Alternatives to nitric oxide

British Medical Bulletin

Volumn 70, Issue , 2004, Pages 119-131

  Lowson, Stuart M ^a  

^a UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENOMEDULLIN; BERAPROST; BOSENTAN; CALCIUM CHANNEL BLOCKING AGENT; ENDOTHELIN; ENDOTHELIN RECEPTOR ANTAGONIST; GLYCERYL TRINITRATE; ILOPROST; NITRIC OXIDE; NITRIC OXIDE DONOR; NITROPRUSSIDE SODIUM; PHOSPHODIESTERASE INHIBITOR; PROSTACYCLIN; PROSTACYCLIN DERIVATIVE; PROSTAGLANDIN; PROSTAGLANDIN E1; SILDENAFIL; TERBOGREL; THROMBOXANE; THROMBOXANE RECEPTOR BLOCKING AGENT; TREPROSTINOL; UNCLASSIFIED DRUG;

ADULTHOOD; BLEEDING; BRONCHOSPASM; CLINICAL TRIAL; DIARRHEA; DRUG COST; DRUG SELECTIVITY; FLUSHING; HEADACHE; HUMAN; HYPOTENSION; HYPOXIA; LEG PAIN; LONG TERM CARE; LUNG BLOOD VESSEL; LUNG VASOCONSTRICTION; NONHUMAN; OUTCOMES RESEARCH; PAIN; PEDIATRICS; PRIORITY JOURNAL; PULMONARY HYPERTENSION; RESPIRATORY TRACT DISEASE; REVIEW; SIDE EFFECT; THROMBOCYTE AGGREGATION INHIBITION; VASODILATATION;

ADMINISTRATION, INHALATION; ADRENOMEDULLIN; ENDOTHELINS; HUMANS; HYPERTENSION, PULMONARY; NITRIC OXIDE DONORS; PEPTIDES; PHOSPHODIESTERASE INHIBITORS; PYRIDINES; THROMBOXANE-A SYNTHASE; VASODILATOR AGENTS;

EID: 11244289469     PISSN: 00071420     EISSN: None     Source Type: Journal    
DOI: 10.1093/bmb/ldh028     Document Type: Review

References (45)

1. Steudel W, Hurford W, Zapol W (1999) Inhaled nitric oxide: basic biology and clinical applications. Anesthesiology, 91, 1090-1121.
2. Rossaint R, Falke K, Lopez F, et al. (1993) Inhaled nitric oxide for the adult respiratory distress syndrome. N Engl J Med, 328, 399-405.
3. Adhikari N, Granton J (2004) Inhaled nitric oxide for acute lung injury: no place for NO? JAMA, 291, 1629-1631.
4. Fishman A (2004) Primary pulmonary hypertension. A look back. J Am Coll Cardiol, 43, S2-S4.
5. Budhiraja R, Tuder R, Hassoun P (2004) Endothelial dysfunction in pulmonary hypertension. Circulation, 109, 159-165.
6. Lowson S (2002) Inhaled alternatives to nitric oxide. Anesthesiology, 96, 1504-1513.
7. Van Heerden P, Barden A, Michalopoulos N, et al. (2000) Dose-response to inhaled aerosolized prostacyclin for hypoxia due to ARDS. Chest, 117, 819-827.
8. Zwissler B, Kemming G, Habler O, et al. (1996) Inhaled prostacyclin versus inhaled nitric oxide in adult respiratory distress syndrome. Am J Respir Crit Care Med, 154, 1671-1677.
9. Haraldsson A, Kieler-Jensen N, Ricksten S (1996) Inhaled prostacyclin for the treatment of pulmonary hypertension after cardiac surgery or heart transplantation: a pharmacodynamic study. J Cardiothorac Vasc Anesth, 10, 864-868.
10. Della Rocca G, Coccia C, Pompei L, et al. (2001) Inhaled aerosolized prostacyclin and pulmonary hypertension during anesthesia for lung transplantation. Transplant Proc, 33, 1634-1636.
11. Dahlem P, van Aalderen W, de Neefe M, et al. (2004) Randomized controlled trial of aerosolized prostacyclin therapy in children with acute lung injury. Crit Care Med, 32, 1055-1060.
12. Haraldson A, Kieler-Jensen N, Wadenvik H, et al. (2000) Inhaled prostacyclin and platelet function after cardiac surgery and cardiopulmonary bypass. Intensive Care Med, 26, 188-194.
13. Augoustides J, Gulp K, Smith S (2004) Rebound pulmonary hypertension and cardiogenic shock after withdrawal of inhaled prostacyclin. Anesthesiology, 100, 1023-1025.
14. Mikhail G, Gibbs S, Richardson G, et al. (1997) An evaluation of nebulized prostacyclin in patients with primary and secondary pulmonary hypertension. Eur Heart J, 18, 1499-1504.
15. Siobal M, Kallet R, Pitttet J, et al. (2003) Description and evaluation of a delivery system for aerosolized prostacyclin. Respir Care, 48, 742-753.
16. Hill L, Pearl R (1999) Combined inhaled nitric oxide and inhaled prostacyclin during experimental chronic pulmonary hypertension. J Appl Physiol, 86, 1160-1164
17. Della Rocca G, Coccia C, Pompei L, et al. (2001) Hemodynamic and oxygenation changes of combined therapy with inhaled nitric oxide and inhaled aerosolized prostacyclin. J Cardiothorac Vasc Anesth, 15, 224-227.
18. Schermuly R, Ghofrani H, Enke B, et al. (1999). Low-dose systemic phosphodiesterase inhibitors amplify the pulmonary vasodilator response to inhaled prostacyclin in experimental pulmonary hypertension. Am J Resp Crit Care Med, 160, 1500-1506.
19. Haraldsson A, Kieler-Jensen N, Ricksten S (2001) The additive pulmonary vasodilatory effects of inhaled prostacyclin and inhaled milrinone in postcardiac surgery patients with pulmonary hypertension. Anesth Analg, 93, 1439-1445.
20. Putensen C, Hormann C, Kleinsasser A, et al. (1998) Cardiopulmonary effects of aerosolized prostaglandin E1 and nitric oxide inhalation in patients with acute respiratory distress syndrome. Am J Respir Crit Care Med, 157, 1743-1747.
21. Hoeper M, Olschewski H, Ghofrani H, et al. (2000) A comparison of the acute hemodynamic effects of inhaled nitric oxide and aerosolized iloprost in primary pulmonary hypertension. J Am Coll Cardiol, 35, 176-182.
22. Olschewski H, Simmoneau G, Sitbon O, et al. (2002) Inhaled iloprost in severe pulmonary hypertension. N Engl J Med, 347, 322-329.
23. Leuchte H, Schwaiblmair M, Baumgartner R, et al. (2004) Hemodynamic response to sildenafil, nitric oxide, and iloprost in primary pulmonary hypertension. Chest, 125, 580-586.
24. Hoeper M, Spiekerkoetter E, Westerkamp V, et al. (2002) Intravenous iloprost for treatment failure of aerosolized iloprost in pulmonary arterial hypertension. Eur Respir J, 20, 339-343.
25. Langer F, Wilhelm W, Tscholl D et al. (2003) Intraoperative inhalation of the long-acting prostacyclin analog iloprost for pulmonary hypertension. J Thorac Cardiovasc Surgery, 126, 874-875.
26. Muller M, Scholz S, Kwapisz M, et al. (2003) Use of inhaled iloprost in a case of pulmonary hypertension during pediatric congenital heart surgery. Anesthesiology, 99, 743-744.
27. Lowson S (2003) Nitric oxide signaling and clinical alternatives to nitric oxide. Semin Cardiothorac Vasc Anesth, 7, 239-252.
28. Simonneau G, Barst R, Galie N, et al. (2002) Continuous subcutaneous infusion of treprostinol, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial. Am J Respir Crit Care Med, 165, 800-804.
29. Mehta S (2003) Drug therapy for pulmonary arterial hypertension. Chest, 124, 2045-2049.
30. Galie N, Humbert M, Vachiery J, et al. (2002) Effects of beraprost sodium, an oral prostacyclin analogue, in patients with pulmonary arterial hypertension: a randomized, double-blind, placebo-controlled trial. J Am Coll Cardiol, 39, 1496-1502.
31. Barst R, McGoon M, McLaughlin V, et al. (2003) Beraprost therapy for pulmonary arterial hypertension. J Am Coll Cardiol, 41, 2119-2125.
32. Atz A, Wessel D (1999) Sildenafil ameliorates the effects of nitric oxide withdrawal. Anesthesiology, 91, 307-310.
33. Atz A, Lefler A, Fairbrother D, Uber W, Bradley S (2002) Sildenafil augments the effect of inhaled nitric oxide for postoperative pulmonary hypertensive crises. J Thorac Cardiovasc Surg, 124, 628-629.
34. Ghofrani H, Wiedermann R, Rose F, et al. (2002) Combination therapy with oral sildenafil and inhaled iloprost for severe pulmonary hypertension. Ann Intern Med, 136, 515-522.
35. Mickelakis E, Tymchak W, Lien D, et al. (2002) Oral sildenafil is an effective and specific pulmonary vasodilator in patients with pulmonary arterial hypertension. Circulation, 105, 2398-2403.
36. Stocker C, Penny D, Brizzard C, et al. (2003) Intravenous sildenafil and inhaled nitric oxide: a randomized trial in infants after cardiac surgery. Intensive Care Med, 29, 1996-2003.
37. Ghofrani H, Wiedemann R, Rose F, et al. (2002) Sildenafil for treatment of lung fibrosis and pulmonary hypertension: a randomized controlled trial. Lancet, 360, 895-900.
38. Adrie C, Holzmann A, Hirani W, et al. (2000) Effects of intravenous Zaprinest and inhaled nitric oxide on pulmonary hemodynamics and gas exchange in an ovine model of acute respiratory distress syndrome. Anesthesiology, 93, 422-430.
39. Rubin L, Badesch D, Barst R, et al. (2002) Bosentan therapy for pulmonary arterial hypertension. N Engl J Med, 346, 896-903
40. Galie N, Hinderliter A, Torbicki A, et al. (2003) Effects of oral endothelin-receptor antagonist bosentan on echocardiographic and Doppler measures in patients with pulmonary arterial hypertension. J Am Coll Cardiol, 41, 1380-1386.
41. Barst R, Langleben D, Frost A, et al. (2004) Sitaxsentan therapy for pulmonary arterial hypertension. Am J Respir Crit Care Med, 169, 441-447.
42. Langleben D, Christman B, Barst R, et al. (2002) Effects of thromboxane synthetase inhibitor and receptor anatagonist terbogrel in patients with primary pulmonary hypertension. Am Heart J, 143, E4.
43. Nagaya N, Okumura H, Uematsu M, et al. (2003) Repeated inhalation of adrenomedullin ameliorates pulmonary hypertension and survival in monocrotaline rats. Am J Physiol, 285, H2125-H2131.
44. Nagaya N, Kyotani S, Uematsu M, et al. (2004) Effects of adrenomedullin inhalation on hemodynamics and exercise capacity in patients with idiopathic pulmonary arterial hypertension. Circulation, 109, 351-356.
45. Yurtseven N, Karaca P, Kaplan M, et al. (2003) Effect of nitroglycerin inhalation on patients with pulmonary hypertension undergoing mitral valve replacement surgery. Anesthesiology, 99, 855-858.